Low-dose anti-VEGF plus laser possible treatment for type 1 ROP in zone 1
Good anatomic results and preservation of central vision field were seen after combined treatment of a low dose of bevacizumab and zone 1 sparing laser ablation in infants with type 1 retinopathy of prematurity in zone 1, according to a study.
Investigators analyzed medical records of 18 eyes of 10 infants who underwent combined 0.25 mg intravitreal Avastin (bevacizumab, Genentech) injections and laser ablation.
Mean gestational age at birth was 24.1 weeks, and mean weight was 628.1 g. All infants had comorbidities, including bronchopulmonary dysplasia, intraventricular hemorrhage and patent ductus arteriosus, and eight infants were born after multigestational pregnancy.
Laser therapy was initiated within a median of 3 days of bevacizumab injection.
In all eyes, neovascular pathology and plus disease regressed within 1 after the bevacizumab treatment, and there were no cases of recurrence. All maculas remained intact at the final follow-up at 84 weeks postmenstrual age, and no systemic adverse events were recorded.
The study authors said the results should be interpreted with caution because no eyes had posterior zone 1 disease.
Disclosure: The authors have no relevant financial disclosures.